Pro-drugs of all non-steroidal anti-inflammatories with free acid function derivatized with an ester group which have the general structural formula given below (I) where A is: aspirin diflunisal benorylate ibufenac diclofenac indomethacin sulindac ketorolac ibuprofen naproxen ketoprofen fenoprofen flurbiprofen mefenamic acid meclof enamic acid flufenamic acid niflumic acid and where in the ester group R can be a sugar (amongst which aldose or ketose pentose or esose selected from a group of D- ...

Composition comprises (a) at least one first compound comprising celecoxib etoricoxib lumiracoxib parecoxib rofecoxib valdecoxib valicoxib and (b) at least one second compound comprising: e.g. indoprofen ibuproxam ketoprofen ketorolac loxoprofen naproxen naproxen sodium oxaprozin pirprofen suprofen tiaprofenic acid and alminoprofen; salicylamide and salicyl salicylate; aceclofenac acemetacin and alclofenac; mefenamic acid flufenamic acid and meclofenamic acid; ampyrone azapropazone and clofezone...

The novel positively charged pro-drugs of arylanthranilic acids in the general formula (1) 'Structure 1' were designed and synthesized. The compounds of the general formula (1) 'Structure 1' indicated above can be prepared from mefenamic acid meclofenamic acid flufenamic acid niflumic acid flunixin and related compounds by reaction with suitable alcohols thiols or amines and coupling reagents such as N N'-Dicyclohexylcarbodiimide N N'-Diisopropylcarbodiimide O-(Benzotriazol-1-yl)-NNN'N'-tetramet...

Pro-drugs of all non-steroidal anti-inflammatories with free acid function derivatized with an ester group which have the general structural formula given below (I) where A is: aspirin diflunisal benorylate ibufenac diclofenac indomethacin sulindac ketorolac ibuprofen naproxen ketoprofen fenoprofen flurbiprofen mefenamic acid meclof enamic acid flufenamic acid niflumic acid and where in the ester group R can be a sugar (amongst which aldose or ketose pentose or esose selected from a group of D- ...

PROBLEM TO BE SOLVED: To provide an anticancer drug effect enhancer which enhances the therapeutic effect by the administration of anticancer drugs in the anticancer drug-resistant carcinoma or cases.

There is described a respiratory disorder therapy for administration twice daily or less comprising a therapeutically effective amount of cetirizine, or a pharmaceutically acceptable derivative thereof, and a therapeutically effective amount of mefenamic acid, or a pharmaceutically acceptable derivative thereof.